Hubbry Logo
DPT vaccineDPT vaccineMain
Open search
DPT vaccine
Community hub
DPT vaccine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
DPT vaccine
DPT vaccine
DPT vaccine
View on Wikipedia
from Wikipedia

DPT vaccine
Global vaccination coverage- diphtheria-tetanus-pertussis (DTP3) immunization[1]
Combination of
Diphtheria vaccineVaccine
Pertussis vaccineVaccine
Tetanus vaccineVaccine
Clinical data
Trade namesAdacel, Boostrix, others
AHFS/Drugs.comMonograph
MedlinePlusa607027
License data
Routes of
administration		Intramuscular injection
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
KEGG

The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus (lockjaw).[13] The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself.[14] The whole cells or antigens will be depicted as either "DTwP"[15] or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular".[16] In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid (and for pertussis, either a dead pathogen or pure antigens) to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.[17]

In the United States, the DPT (whole-cell) vaccine was administered as part of the childhood vaccines recommended by the Centers for Disease Control and Prevention (CDC) until 1996, when the acellular DTaP vaccine was licensed for use.[18]

History

[edit]
An adherent, dense, grey pseudomembrane covering the tonsils is classically seen in diphtheria

Diphtheria and tetanus toxoids and whole-cell[16] pertussis (DTP; now also "DTwP" to differentiate from the broader class of triple-combination vaccines)[15] vaccination was licensed in 1949.[19] Since the introduction of the combination vaccine, there has been an extensive decline in the incidence of pertussis, or whooping cough, the disease which the vaccine protects against. Additionally, the rates of disease have continued to decline as more extensive immunization strategies have been implemented, including booster doses and increased emphasis on increasing health literacy.[20]

In the 20th century, the advancements in vaccinations helped to reduce the incidence of childhood pertussis and had a dramatically positive effect on the health of populations in the United States.[21] However, in the early 21st century, reported instances of the disease increased 20-fold due to a downturn in the number of immunizations received and resulted in numerous fatalities.[22] During the 21st century, many parents declined to vaccinate their children against pertussis for fear of perceived side effects, despite scientific evidence showing vaccines to be highly effective and safe.[22] A study published in 2009 concluded the largest risk among unvaccinated children is not the contraction of side effects, but rather the disease that the vaccination aims to protect against.[22]

DTP vaccines with acellular pertussis (DTaP; see below) were introduced in the 1990s. The reduced range of antigens causes fewer side effects, but results in a more expensive, shorter-lasting,[23] and possibly less protective vaccine compared to DTwP.[24] High-income countries have mostly switched to DTaP. As of 2023, global production of aP remains limited.[25]

Vaccination rates

[edit]

In 2016, the US Centers for Disease Control and Prevention (CDC) reported that 80.4% of children in the US had received four or more DTaP vaccinations by 2 years of life.[26] Vaccination rates for children aged 13–17 with one or more TDaP shots was 90.2% in 2019.[26] Only 43.6% of adults (older than 18 years of age) have received a TDaP shot in the last 10 years.[26] The CDC aimed to increase vaccination rate among 2-year-olds from 80.4% to 90.0%[27]

The World Health Organization (WHO) estimated that 89% of people globally had received at least one dose of DTP vaccine and 84% had received three doses of the vaccine, completing the WHO-recommended primary series (DTP3).[28] The WHO tracks DTP3 completion rates among one-year-olds on a yearly basis. The yearly DTP3 completion rate is considered a good proxy for the completeness of childhood vaccination in general,[29] and numbers of children who have not received a first dose of DTP are used as a proxy for those who are not reached by vaccination programs at all (termed zero-dose children).[30]

Combination vaccines with acellular pertussis

[edit]

DTaP and Tdap are both combination vaccines against diphtheria, tetanus, and pertussis. The "a" indicates that the pertussis toxoids are acellular, while the lower-case "d" and "p" in "Tdap" indicate smaller concentrations of diphtheria toxoids and pertussis antigens.[31]

DTaP

[edit]

DTaP (also DTP and TDaP) is a combination vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular.[32] This is in contrast to whole-cell, inactivated DTP (or DTwP).[15] The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity.[23] Because it uses fewer antigens than the whole-cell vaccines, it is considered to cause fewer side effects, but it is also more expensive.[23] Research suggests that the DTwP vaccine is more effective than DTaP in conferring immunity, because DTaP's narrower antigen base is less effective against current pathogen strains.[24]

Tdap

[edit]

Tdap (also TDP) is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. It was licensed in the United States for use in adults and adolescents in June 2005.[33] Two Tdap vaccines are available in the US. In January 2011, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended the use of Tdap in adults of all ages, including those aged 65 years of age and older.[34] In October 2011, in an effort to reduce the burden of pertussis in infants, the ACIP recommended that unvaccinated pregnant women receive a dose of Tdap. In October 2012, the ACIP voted to recommend the use of Tdap during every pregnancy.[35][36] The ACIP and Canada's National Advisory Committee on Immunization (NACI) recommended that both adolescents and adults receive Tdap in place of their next Td booster (recommended to be given every ten years).[37][38][39][33] Tdap and Td can be used as prophylaxis for tetanus in wound management. People who will be in contact with young infants are encouraged to get Tdap even if it has been less than five years since Td or TT to reduce the risk of infants being exposed to pertussis. NACI suggests intervals shorter than five years can be used for catch-up programs and other instances where programmatic concerns make five-year intervals difficult.[40]

The World Health Organization recommends a pentavalent vaccine, combining the DTP vaccine with vaccines against Haemophilus influenzae type B and hepatitis B. Evidence on how effective this pentavalent vaccine is compared to the individual vaccines has not yet been determined.[41]

A 2019 study found that state requirements mandating the use of the Tdap vaccine "increased Tdap vaccine take-up and reduced pertussis (whooping cough) incidence by about 32%."[42]

[edit]

Excluding pertussis

[edit]

DT and Td vaccines lack the pertussis component.[43][44][45] The Td vaccine is administered to children over the age of seven as well as to adults. It is most commonly administered as a booster shot every 10 years.[43] The Td booster shot may also be administered as protection from a severe burn or dirty wound.[43] The DT vaccine is given to children under the age of seven who are unable to receive the pertussis antigen in the DTaP vaccine due to a contraindication.[46]

Additional targets

[edit]
Main articles: DTaP-IPV vaccine, DTaP-IPV-HepB vaccine, Pentavalent vaccine, and Hexavalent vaccine

In the United States, a combined inactivated polio (IPV), DTaP, and hepatitis B DTaP-IPV-HepB vaccine is available for children.[47][48] In the UK, all babies born on or after 1 August 2017 are offered a hexavalent vaccine: DTaP, IPV, Haemophilus influenzae, and hepatitis B (DTaP-Hib-HepB-IPV in short).[49]

As of 2023, most of the DTP vaccine procured by UNICEF is of the DTwP-HepB-Hib (pentavalent whole-cell) type. The UNICEF plans to procure the DTwP-HepB-Hib-IPV (hexavalent whole-cell) vaccine starting in 2024.[25]

Contraindications

[edit]

The DPT vaccine should be avoided in persons who experienced a severe allergic reaction, such as anaphylaxis, to a past vaccine containing tetanus, diphtheria, or pertussis. It should also be avoided in persons with a known severe allergy to an ingredient in the vaccine. If the reaction was caused by tetanus toxoids, the CDC recommends considering a passive immunization with tetanus immune globulin (TIG) if a person has a large or unclean wound.[50] The DPT vaccine should also be avoided if a person developed encephalopathy (seizures, coma, declined consciousness) within seven days of receiving any pertussis-containing vaccine and the encephalopathy cannot be traced to another cause.[51] A DT vaccine is available for children under the ages of seven who have contraindications or precautions to pertussis-containing vaccines.[52]

Side effects

[edit]

DTaP

[edit]

Common side effects include soreness where the shot was given, fever, irritability, tenderness, loss of appetite, and vomiting.[32] Most side effects are mild to moderate and may last from one to three days.[32] More serious but rare reactions after a DTaP vaccination may include seizures, lowered consciousness, or a high fever over 105 °F (41 °C).[13] Allergic reactions are uncommon, but are medical emergencies. Signs of an allergic reaction include hives, dyspnea, wheezing, swelling of face and throat, syncope, and tachycardia and the child should be rushed to the nearest hospital.[53]

Tdap

[edit]

Common side effects include pain or swelling where the shot was given, mild fever, headache, tiredness, nausea, vomiting, diarrhea, and stomach ache.[32] Allergic reactions are possible and have the same presentation and indications as described above for allergic reactions in DTaP. Any individual who has experienced a life-threatening allergic reaction after receiving a previous dose of diphtheria, tetanus, or pertussis containing vaccine should not receive the Tdap vaccination.[32]

In pregnant women, research suggests that Tdap administration may be associated with an increased risk of chorioamnionitis, a placental infection.[54] Increased incidence of fever is also noted in pregnant women.[54] Despite the observed increase in incidence of chorioamnionitis in pregnant women following Tdap administration, there has been no observed increase in the incidence of preterm birth, for which chorioamnionitis is a risk factor.[54][55] Research has not discerned an association between Tdap administration during pregnancy and other serious pregnancy complications such as neonatal death and stillbirth.[54][55] An association between Tdap administration during pregnancy and pregnancy-related hypertensive disorders (such as pre-eclampsia) has not been identified.[55]

Immunization schedules and requirements

[edit]

Australia

[edit]

In Australia, the DTP vaccine is part of the National Immunisation Program (NIP). The vaccine is administered to infants in a series of doses: the first three doses are given at 2, 4, and 6 months of age, followed by a fourth dose at 18 months and a fifth dose at 4 years. Adolescents receive a single booster dose at 12–13 years.

Adults are recommended to receive a dTpa booster every 10 years, especially those in close contact with infants. Pregnant women are advised to receive a dTpa booster during each pregnancy, ideally between 20 and 32 weeks of gestation, to protect newborns from pertussis.[56]

France

[edit]

In France, children are given DTaP-Hib-HepB-IPV vaccines at 2 months (first dose) and 4 months (second dose) with a booster at 11 months of age. A tetravalent booster for diphtheria, pertussis, tetanus and poliomyelitis is given at 6 years, at 11–13 years, then at 25, 45, 65 years of age, then every 10 years.[57][58]

Netherlands

[edit]

In the Netherlands, pertussis is known as kinkhoest and DKTP refers to the DTaP-IPV combination vaccine against diphtheria, kinkhoest, tetanus, and polio. DTaP is given as part of the National Immunization Program.[59]

United Kingdom

[edit]

In the United Kingdom, Td/IPV[60] is called the "3-in-1 teenage booster" and protects against tetanus, diphtheria and polio. It is given by the NHS to all teenagers aged 14 (the hexavalent vaccine is given to infants and provides the first stage of protection against diphtheria, tetanus, and polio, as well as pertussis, Haemophilus influenzae type B and hepatitis B). Subsequent boosters are recommended for foreign travellers where more than 10 years has passed since their last booster.[61] This is provided on the NHS free of charge due to the significant risk that an imported case of polio could pose to public health in Britain.[62]

United States

[edit]

The standard immunization regimen for children within the United States is five doses of DTaP between the ages of two months and fifteen years. To be considered fully vaccinated, the Centers for Disease Control and Prevention (CDC) typically requires five doses of Tdap.[63] The CDC recommends that children receive their first dose at two months, the second dose at four months, the third dose at six months, the fourth dose between 15 and 18 months, and the fifth dose between 4–6 years. If the fourth dose of the DTaP immunization regimen falls on or subsequent to the recipient's fourth birthday, the CDC states that only four doses are required to be fully vaccinated.[63] In the instance that an individual under 18 has not received the DTaP vaccine, individuals should be vaccinated on the schedule in accordance with the vaccination "catch up schedule" provided by the CDC.[63]

Infants younger than twelve months of age, specifically less than three months of age, are at highest risk of acquiring pertussis.[64] In U.S., there is no current tetanus-diphtheria-pertussis vaccination (whooping cough) recommended or licensed for new born infants.[64] As a result, in their first few months of life, unprotected infants are at highest risk of life-threatening complications and infections from pertussis. Infants should not receive pertussis vaccination younger than six weeks of age.[65] Ideally, Infants should receive DTaP (name of whooping cough vaccine for children from age 2 months through 6 years) at 2, 4, 6 months of age and they are not protected until the full series is completed.[64] To protect infants younger than twelve months of age not vaccinated with Tdap against pertussis, ACIP also recommends adults (e.g., parents, siblings, grandparents, childcare providers, and healthcare personnel) and children to receive Tdap at least two weeks before being in contact with the infant.[51]

The CDC recommends that adults who have received their childhood DTP series receive a Td or Tdap booster every ten years.[66][67] For adults that have not received the DTP series, the CDC recommends a three-part vaccine series followed by a Td or Tdap booster every ten years.[66]

In pregnancy

[edit]

According to guidelines of the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC), one dose of Tdap is recommended during each pregnancy to ensure protection against pertussis in newborn infants.[36] Optimal timing to administer a dose of Tdap during each pregnancy is between 27 through 36 weeks gestation.[36] If Tdap is administered early in pregnancy, it is not recommended to administer again during the 27 through 36 weeks gestation period as only one dose is recommended during pregnancy.[68] In October 2022, Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) was approved for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age.[69]

Pregnant women who have not previously vaccinated with Tdap (i.e., have never received DTP, DTaP, or DT as child or Td or TT as an adult) are recommended to receive a series of three Td vaccinations starting during pregnancy to ensure protection against maternal and neonatal tetanus.[70] In such cases, administration of Tdap is recommended after 20 weeks' gestation,[71][36] and in earlier pregnancy a single dose of Tdap can be substituted for one dose of Td, and then the series completed with Td.[70][36] For pregnant women not previously vaccinated with Tdap, if Tdap is not administered during pregnancy, it should be administered immediately postpartum.[51] Postpartum administration of TDaP is not equivalent to administration of the vaccination during pregnancy.[72] Because the vaccine is administered postpartum, the mother is unable to develop antibodies that can be transferred to the infant in utero, consequently, leaving the infant vulnerable to the diseases preventable by the Tdap Vaccine.[72] Postpartum administration of the TdaP vaccine to the mother seeks to reduce the likelihood that the mother will contract disease that can be subsequently passed on the infant, albeit there will still be a two-week period prior to the protective effects of the vaccine setting in.[72] Postpartum administration is an extension of the concept of "cocooning", a term that refers to the full vaccination of all individuals that may come into direct contact with the infant.[72] Cocooning, like postpartum Tdap administration, is not recommended by the CDC.[72] Cocooning depends on ensuring full vaccination of all individuals that the infant may come into contact with, and there may be financial, administrative or personal barriers that preclude full and timely vaccination of all individuals within the "cocoon".[72]

Brand names

[edit]

Australia

[edit]
TDaP Vaccines in Australia
Trade name Approval date Comments
Adacel[73] 2005[74] Adacel is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged ten years and over as a booster following primary immunisation[74] and is informally known as 'triple antigen' in Australia.[75]
Adacel Polio[76] 2006[77] Adacel Polio is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged four years and older as a booster following primary immunization.[77]

United States

[edit]

As of January 2020, there are seven DTaP vaccines and two Tdap vaccines licensed and available for use in the United States.[78][79] All of them are indicated as childhood vaccinations with the schedules as follows:

DTaP Vaccines in the US
Trade name Approval date Comments Contraindications
Daptacel[80] 2002[81] For use in ages six weeks through six years as a five-dose series at 2, 4, and 6 months (6–8 weeks apart) and at 15–20 months of age and at 4–6 years.[80]
  • Severe allergic reaction (anaphylaxis) after a previous dose of Daptacel or tetanus, diphtheria, or pertussis containing vaccine.
  • Encephalopathy (coma, prolonged seizures, and decreased level of consciousness) within seven days of a previous dose of a pertussis containing vaccine.
  • Progressive neurologic disorder (spasms, epilepsy, progressive encephalopathy)[80]
Infanrix[82] 1997[83] For use in ages six weeks through six years (before the seventh birthday) as a five-dose series as: a three-dose course at 2, 5, and 6 months (4–8 weeks apart), followed by a two booster doses at 15–20 months of age and 4–6 years of age.[82]
  • Severe allergic reaction (anaphylaxis) after a previous dose of Infanrix or tetanus, diphtheria, or pertussis-containing vaccine.
  • Encephalopathy (coma, prolonged seizures, and decreased level of consciousness) within seven days of a previous dose of a pertussis containing vaccine.
  • Progressive neurologic disorder (spasms, epilepsy, progressive encephalopathy)[82]
Kinrix[84] 2008[85] DTaP-IPV vaccine; also immunizes against poliomyelitis. Kinrix can be used for the fifth (last) dose in the DTaP immunization series and the fourth dose in the IPV immunization series in children aged 4–6 years old (before the seventh birthday) whose previous DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose.[84]
  • Severe allergic reaction (anaphylaxis) after a previous dose of any vaccine containing diphtheria, tetanus, pertussis or poliovirus
  • Severe allergic reaction (anaphylaxis) to any ingredient in any of Kinrix's vaccines
  • Encephalopathy (declining level of consciousness, coma, seizure) within seven days of receiving any pertussis-containing vaccine
  • Progressive neurologic disorders (spasms, epilepsy)[84]
Pediarix[86] 2002[87] DTaP-IPV-HepB vaccine; also immunizes against hepatitis B and poliomyelitis as a three-dose series in infants two, four, and six months (4–8 weeks apart).[86]
  • Severe allergic reaction (anaphylaxis) after a previous dose of Pediarix, any type of ingredient of Pediarix, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine or H. influenzae type b vaccine.
  • Encephalopathy within seven days of pertussis-containing vaccine.
  • Progressive neurologic disorder of spasms, epilepsy until the condition has stabilized.[86]
Pentacel[88] 2008[89] DTaP-IPV/Hib vaccine; also immunizes against invasive Haemophilus influenza type b and poliomyelitis. It is a four-dose series given at: 2, 4, and 6 months, and at 15–18 months of age.[88]
  • Severe allergic reaction (anaphylaxis) after a previous dose of Pentacel, any type of ingredient of Pentacel, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine or H. influenzae type b vaccine.
  • Encephalopathy within seven days of pertussis-containing vaccine.
  • Progressive neurologic disorder of spasms, epilepsy until the condition has stabilized.[88]
Quadracel[90] 2015[91] DTaP-IPV vaccine; also immunizes against poliomyelitis. It is approved for use as a fifth dose for children aged 4–6 years old in the DTaP vaccination series and as a fourth or fifth dose in the inactivated polio (IPV) series.[90]
  • Severe allergic reaction (anaphylaxis) after a previous dose of Quadracel, any type of ingredient of Quadracel, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine or H. influenzae type b vaccine.
  • Encephalopathy within seven days of pertussis-containing vaccine.
  • Progressive neurologic disorder of spasms, epilepsy until the condition has stabilized.[90]
Vaxelis[92] 2018[93] Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib) in children aged six weeks through four years of age (prior to fifth birthday).
TDaP Vaccines in the US
Trade name Approval date Comments Contraindications
Adacel[94] 2005[95] For use in ages 10 through 64 as an active booster immunization against tetanus, diphtheria, and pertussis. It may also be administered as prophylaxis for wound management.[94] It has not been shown to be safe or effective as a primary immunization or to complete the series.
  • Hypersensitivity reaction (anaphylaxis) after a previous dose of Adacel, any type of ingredient of Adacel, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine or H. influenzae type b vaccine.
  • Encephalopathy (coma, seizure, loss of consciousness) within seven days of pertussis-containing vaccine.
  • Progressive neurologic disorder of spasms, epilepsy until the condition has stabilized.[94]
Boostrix[96] 2005[97] For use in ages ten and older as a single intramuscular injection into the deltoid as a booster immunization against tetanus, diphtheria, and pertussis. It may also be administered as prophylaxis for wound management.[96]
  • Hypersensitivity reaction (anaphylaxis) after previously receiving a vaccine containing any form of tetanus toxoid, diphtheria toxoid, or pertussis-containing antigen.
  • Hypersensitivity reaction (anaphylaxis) to any ingredient within a previously administered Boostrix vaccine.
  • Encephalopathy (coma, seizure, loss of consciousness) progression within seven days of receiving a vaccine with antigens from pertussis.[96]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

DPT vaccine

View on Grokipedia
from Grokipedia
The DPT vaccine, also denoted as DTP, is a combination consisting of , , and whole-cell components, developed in the 1940s to protect against the bacterial diseases , , and pertussis (). Administered in a primary series of doses typically starting in infancy, it induces immunity by stimulating production against the toxins produced by and , and against bacteria. Widespread use following its licensure led to substantial declines in morbidity and mortality from these vaccine-preventable diseases in countries with high coverage. The vaccine's pertussis component, derived from killed whole , demonstrated robust effectiveness in preventing severe and , particularly when compared to later acellular formulations, with studies indicating longer-lasting immunity that better curbs transmission. However, the whole-cell was associated with higher rates of local reactions such as pain and swelling, as well as systemic effects including fever and, rarely, more serious events like seizures or hypotonic-hyporesponsive episodes, prompting safety concerns and litigation in the and that temporarily reduced uptake in some regions. These reactogenicity issues drove the transition to acellular pertussis vaccines (DTaP) in the , which reduced adverse reactions but exhibited faster waning protection, especially beyond four years post-vaccination, correlating with adolescent and adult pertussis outbreaks despite high childhood coverage. This shift has raised questions about the trade-offs in vaccine design, as acellular versions permit asymptomatic carriage and fail to fully restore population-level as effectively as the original formulation.

Diseases Targeted

Diphtheria

Diphtheria is caused by toxin-producing strains of the gram-positive bacterium , which colonizes the mucous membranes of the upper or . The disease's severe manifestations result from an elaborated by strains lysogenized by a carrying the tox ; this toxin inhibits eukaryotic protein synthesis by of 2, causing cell death and local tissue necrosis. The hallmark clinical feature is formation of an adherent pseudomembrane, a grayish-white fibrinopurulent composed of necrotic , , and inflammatory cells, typically appearing on the tonsils, , or within 2–3 days of symptom onset. This membrane can extend to obstruct the airway, leading to asphyxiation, while systemic toxin absorption may cause , , or renal damage. Initial symptoms include , low-grade fever, , and hoarseness; cervical produces a "bull neck" appearance in severe cases, with skin infections manifesting as punched-out ulcers covered by similar membranes. Transmission occurs person-to-person via respiratory droplets generated by coughing or sneezing, or through direct contact with nasopharyngeal secretions, saliva, or exudates from cutaneous lesions; asymptomatic carriers harboring toxigenic strains in the throat or nose facilitate spread. The bacterium survives longer in environments of poor hygiene and overcrowding, with highest incidence among unvaccinated children under 5 years and in communities with suboptimal sanitation. In the pre-vaccine era, imposed substantial mortality, with the recording 100,000–200,000 cases annually during the , resulting in 13,000–15,000 deaths, primarily among young children despite availability since the that reduced case-fatality rates to 5–10%. Peak incidence exceeded 200,000 cases in 1921 alone, underscoring the disease's toll before toxoid immunization curtailed transmission.

Tetanus

Tetanus is a toxin-mediated disease caused by the bacterium Clostridium tetani, an whose spores are ubiquitous in , dust, and animal feces worldwide. These hardy spores, resistant to heat, boiling, and many disinfectants, germinate in anaerobic environments such as deep , contaminated cuts, or injuries with devitalized tissue, where they multiply and release tetanospasmin, a potent . Unlike contagious infections, tetanus cannot spread person-to-person; exposure occurs solely through environmental contamination of wounds, making personal hygiene and wound care insufficient to prevent germination in high-risk injuries. The tetanospasmin toxin travels retrogradely along motor neurons to the central nervous system, where it blocks inhibitory neurotransmitters like glycine and GABA, resulting in unopposed muscle contraction and spastic paralysis. Initial symptoms include trismus (lockjaw), dysphagia, and rigidity of the jaw and neck muscles, progressing to generalized spasms, opisthotonos, and autonomic instability, with an incubation period typically of 3 to 21 days. Without prompt intervention such as antitoxin administration, the case-fatality rate approaches 100%, driven by respiratory failure, cardiac arrhythmias, and rhabdomyolysis; even with modern supportive care in resource-limited settings, mortality remains 50-80%. Prior to widespread vaccination, inflicted a heavy global burden, with estimates of up to 1 million annual deaths, predominantly in unvaccinated populations exposed through agricultural work, , or trauma in developing regions. The disease's persistence stems from the spores' environmental ubiquity—found in nearly all soils and persisting for years—rendering complete avoidance impossible without , which induces neutralizing antibodies against the toxin to avert clinical manifestation upon exposure. This underscores tetanus vaccination's role as the sole reliable preventive measure, distinct from or wound management alone.

Pertussis

Pertussis, commonly known as , is an acute, highly contagious bacterial infection of the respiratory tract caused by . The pathogen primarily affects the ciliated epithelium of the bronchi and bronchioles, leading to toxin-mediated damage that impairs clearance of respiratory secretions. Transmission occurs via airborne respiratory droplets from coughing or sneezing infected individuals, with secondary attack rates exceeding 80% among susceptible household contacts. The typically ranges from 5 to 10 days. The disease progresses in stages: an initial catarrhal phase resembling a minor upper , followed by the paroxysmal marked by intense bouts of —often 15 or more daily—that can last 1 to 10 weeks. These fits are characterized by rapid, explosive coughs ending in a high-pitched inspiratory whoop as the patient gasps for air, sometimes accompanied by , vomiting, or exhaustion. In infants, particularly those under six months, symptoms may manifest as apneic spells without the whoop, heightening risks of sudden . The convalescent phase involves gradual resolution of cough over weeks to months. Complications arise from mechanical effects of coughing, bacterial , or toxin-induced hypoxia, including (the most common serious issue), seizures, , subconjunctival hemorrhages, and rib fractures in severe cases. Infants face the highest morbidity and mortality, with risks amplified by immature immunity and smaller airways. In the pre-vaccine era before the , the experienced an estimated 200,000 pertussis cases annually, with 4,000 to 9,000 deaths—predominantly among children under five years old, reflecting the disease's toll on unvaccinated pediatric populations. This baseline underscores pertussis's role as a leading cause of vaccine-preventable , driving focused efforts on its control amid ongoing debates over intervention strategies.

Vaccine Development and Formulations

Historical Development of Whole-Cell Vaccines

In the early 1920s, French veterinarian Gaston Ramon developed diphtheria toxoid by treating with and heat, neutralizing its toxicity while preserving ; this method, demonstrated in 1923, enabled production of a vaccine that induced protective antibodies without causing disease. Similarly, toxoid was created using inactivation of tetanus toxin, with initial formulations available by 1924 and refined for broader use in the 1930s, including military applications during that demonstrated substantial reductions in tetanus cases among vaccinated troops. Development of the whole-cell began in the 1930s at the Department of Health, where bacteriologists Pearl Kendrick and Grace Eldering isolated strains from clinical cases and produced an using killed whole bacterial cells suspended in saline after purification and sterilization with formalin or other agents. Their work culminated in field trials starting in 1934, including a 1939 controlled study in schools showing the vaccine reduced pertussis incidence by approximately 80% compared to unvaccinated controls. The combination diphtheria-tetanus-pertussis (DTP) vaccine, incorporating and toxoids with the whole-cell pertussis component, was licensed for use in the United States on May 4, 1949, following safety and potency evaluations by federal regulators. Early efficacy data from U.S. and European trials in the and indicated 70-90% protection against pertussis with multiple doses, prompting rapid post-World War II adoption in national immunization programs. This widespread rollout correlated with over 90% declines in reported and cases in the U.S. by the , alongside sharp reductions in pertussis morbidity and mortality from pre-vaccine peaks exceeding 200,000 annual cases.

Transition to Acellular Pertussis Components

Concerns over adverse events associated with the whole-cell pertussis component of DTP vaccines, including high fevers exceeding 40.5°C in up to 5-10% of recipients, persistent , hypotonic-hyporesponsive episodes, and febrile seizures, intensified in the and , particularly after reports linking the vaccine to rare but severe reactions. In , where pertussis vaccination had been mandatory since 1948, the government temporarily suspended routine immunization in 1975 following the deaths of two infants within 24 hours of receiving whole-cell vaccine doses, resulting in vaccination coverage dropping from 78% to 14% and a pertussis resurgence with over 100,000 cases by 1979. This prompted Japanese researchers to develop acellular pertussis vaccines using purified bacterial antigens, with the first formulation—containing inactivated (PT) and filamentous (FHA)—licensed for routine use in 1981 after trials demonstrating efficacy rates of 54-80% against culture-confirmed pertussis while eliciting fewer local reactions than whole-cell vaccines. Acellular vaccines addressed whole-cell reactogenicity by excluding bacterial cellular components and instead incorporating detoxified PT, FHA, and sometimes additional antigens like pertactin or fimbriae, reducing systemic side effects such as fever and seizures by 50-90% in comparative trials. International efficacy trials in the early 1990s, including Swedish placebo-controlled studies and German, Italian, and Swedish multicenter evaluations, confirmed short-term protective efficacy of 70-85% for multi-component acellular vaccines against WHO-defined pertussis after three doses, comparable to whole-cell vaccines' 80-90% in similar short-term assessments, but with markedly lower incidences of swelling (1-5% vs. 20-30%), redness, and irritability. These data influenced regulatory shifts; the U.S. Food and Drug Administration licensed the first DTaP vaccine (ACEL-IMUNE) in December 1991 for booster doses (fourth and fifth) in children aged 15 months to 6 years, initially limiting primary series use to whole-cell due to ongoing efficacy evaluations. By the mid-1990s, accumulating trial evidence and safety profiles led to broader adoption, with the U.S. Advisory Committee on Immunization Practices recommending acellular vaccines for the entire primary series in infants by 1996, phasing out whole-cell formulations by 1997 amid declining U.S. pertussis incidence from 15,000 cases annually in the 1980s. The adopted guidelines for acellular pertussis components in 1996 and endorsed their use as a safe alternative to whole-cell vaccines in 1998, facilitating global rollout in industrialized nations during the decade, though whole-cell remained predominant in low-resource settings due to differences. This transition prioritized reactogenicity reduction over long-term duration, with acellular vaccines administered at similar schedules (e.g., 2, 4, 6 months) but requiring earlier boosters to maintain coverage.

Current Formulations and Combinations

The DTaP vaccine, intended for pediatric use in infants and young children, contains inactivated and toxoids combined with acellular pertussis antigens, typically including 2 to 5 purified components such as detoxified (PT, 10-25 µg), filamentous hemagglutinin (FHA, 5-25 µg), pertactin (PRN, 3-8 µg), and fimbriae types 2 and 3 (FIM, 5 µg in some formulations). The toxoid dose is higher, ranging from 15 to 30 Lf units per 0.5 mL dose, to elicit robust immunity in children. Aluminum salts, such as aluminum (0.33-0.5 mg aluminum per dose), serve as the adjuvant to enhance immunogenicity, while residual (≤5-100 µg) from manufacturing is present in trace amounts; most formulations are thimerosal-free. In contrast, the Tdap vaccine, formulated for adolescents, adults, and boosters, features reduced quantities of toxoid (2-5 Lf units) and pertussis antigens (e.g., PT 2.5-8 µg, FHA 5-23 µg, PRN 3 µg) compared to DTaP, with toxoid maintained at full strength (5-10 Lf units), to minimize reactogenicity while providing protection. This formulation uses similar aluminum-based adjuvants (0.3-0.33 mg aluminum) and avoids thimerosal in U.S.-licensed products, though some international variants may include 2-phenoxyethanol as a . Combination vaccines integrate DTaP or Tdap components with other s for efficiency in immunization schedules. Pentavalent formulations, such as DTaP-IPV-Hib, add inactivated (IPV, types 1-3 at 40-80 D-antigen units) and type b (Hib) conjugate to protect against five diseases in children aged 6 weeks to 4 years. Hexavalent vaccines further incorporate surface antigen (10-20 µg), as in DTaP-IPV-Hib-HepB, enabling simultaneous prevention of six diseases with aluminum adjuvants and no thimerosal; these are licensed for infants from 6 weeks and used in schedules like the UK's since 2025 updates. Such combinations maintain comparable antigen levels to standalone DTaP but may show minor immune interference, like reduced Hib responses, requiring monitoring of antibody titers.

Efficacy and Duration of Protection

Protection Against and

The toxoid component of the DPT vaccine induces protective levels in nearly all recipients after a primary series of three doses, with estimates ranging from 87% to 97% against symptomatic . Serological studies correlate protection with concentrations above 0.01 IU/mL, similar to tetanus, and demonstrate antibody persistence for at least 10 years post-, with many individuals maintaining protective levels beyond 30 years without boosters. However, gradual waning occurs, necessitating decennial boosters to sustain lifelong immunity, as evidenced by modeling showing five doses predict long-term protective titers in the absence of further vaccination. Breakthrough cases of are rare among fully vaccinated individuals but occur primarily in under-vaccinated populations, underscoring the vaccine's role in individual protection. At population levels, against diphtheria requires approximately 85% coverage with the vaccine, based on the disease's of 6–7, beyond which transmission is significantly curtailed. The tetanus toxoid component exhibits near-100% efficacy following a complete series, inferred from universal achievement of protective levels above 0.01 IU/mL, which neutralize the tetanospasmin toxin produced by .

Pertussis Vaccine Performance and Waning Immunity

The whole-cell (wP) demonstrates efficacy estimates of 70-90% against laboratory-confirmed disease in controlled trials, with protection persisting for 5-10 years or longer before significant waning. In contrast, the acellular pertussis vaccine (aP), introduced to reduce reactogenicity, shows initial efficacy of 80-85% in short-term trials but exhibits more rapid decline, often dropping to 10-50% effectiveness within 4-5 years post-vaccination. For aP components in DTaP, partial protection begins within 1-2 weeks after the first dose, typically administered around 2 months of age, with initial immune responses detectable within 7-14 days and offering good but incomplete protection against pertussis in infants. This difference arises from aP's targeted antigens (e.g., and filamentous ) inducing Th2-biased immunity that fails to generate robust, long-lasting memory responses compared to wP's broader stimulation of Th1 and Th17 pathways. Swedish placebo-controlled trials in the 1990s, involving over 3,000 infants, established aP's short-term non-inferiority to wP, with two- and five-component aP formulations achieving 54-85% against culture-confirmed pertussis with paroxysmal lasting at least 21 days during the primary two-year follow-up. However, extended of these cohorts revealed inferior long-term protection for aP, with relative efficacy falling below 50% after three years, particularly against milder or shorter-duration illness, underscoring wP's superior durability despite higher initial reactogenicity. Real-world observational data corroborate this, showing post-fifth-dose aP vaccine effectiveness declining by approximately 42% annually in children, rendering adolescents susceptible to despite prior dosing. Maternal aP vaccination transfers antibodies to infants, providing transient protection that wanes within months, leaving a vulnerability window before the infant's primary series begins at 2 months of age. This rapid decay, observed in cohort studies, correlates with antibody half-lives of 4-6 weeks for IgG, insufficient to bridge high-risk early infancy without risking blunting of the infant's own immune priming. Adolescent and adult boosters with Tdap temporarily restore levels and reduce symptomatic disease risk for 1-3 years, but fail to durably prevent nasopharyngeal colonization or onward transmission, as evidenced by models where aP-vaccinated hosts shed asymptomatically. studies indicate boosters do not eliminate transmission reservoirs in partially immune populations, contributing to sustained circulation despite high coverage.

Evidence from Outbreaks and Vaccine Failure Cases

In the United States, pertussis cases surged to 48,277 in 2012—the highest annual total since 1955—despite national coverage rates for the three-dose DTaP primary series exceeding 84% among children under 2 years old. Similar outbreaks occurred in prior years, including over 9,000 cases in California in 2010 and elevated incidence in Washington state in 2012, with 2,520 cases reported by mid-year. A substantial proportion of these cases—up to 80% in some pediatric cohorts—occurred in fully vaccinated individuals, demonstrating breakthrough infections even with age-appropriate dosing. Vaccinated persons exhibited milder symptoms compared to unvaccinated ones but remained capable of transmitting Bordetella pertussis, as evidenced by household transmission studies and epidemiological modeling, which indicate that acellular vaccines reduce disease severity without fully blocking colonization or spread. Vaccine failure in pertussis is distinguished as primary (lack of initial immune response post-vaccination) or secondary (waning protection over time). Primary failure rates for acellular pertussis components in DTaP vaccines are estimated at 5-10% in children, reflecting incomplete seroconversion or insufficient antibody titers against key antigens like pertussis toxin. Secondary failures predominate, with protection against infection waning to near zero within 4-5 years after the last dose, accounting for over 80% of breakthroughs in adolescents and adults during outbreaks; this is corroborated by cohort studies showing hazard ratios for pertussis increasing exponentially with time since last vaccination. These patterns question herd immunity thresholds, as models predict sustained transmission when vaccinated individuals harbor and shed the pathogen asymptomatically, even at coverage levels above 90%. Internationally, Australia's pertussis epidemics in the late and exemplify resurgence amid high immunization rates, with coverage for the primary series averaging 92-95% yet notification rates peaking at over 30,000 cases in 2012. effectiveness against notified disease dropped to below 70% within 3-5 years post-priming, with adolescents comprising a disproportionate share of cases due to immunity decay. Contributing factors include antigenic divergence in circulating strains, such as pertactin-deficient variants that evade vaccine-induced antibodies while maintaining , a observed in over 80% of Australian isolates by 2014. Antigenic drift in B. pertussis populations has been linked to these failures, with shifts in key vaccine targets like pertactin (prn) and fimbrial antigens (fim) reducing cross-protection from acellular formulations calibrated to earlier strains. Phylogenetic analyses from multiple countries show clonal expansions of drifted genotypes post-acellular introduction, correlating with epidemic waves despite vaccination; for instance, prn-negative strains proliferated in and the , potentially selected by immune pressure from widespread DTaP use. This evolutionary adaptation, combined with incomplete transmission blockade, sustains outbreaks in vaccinated cohorts, challenging reliance on current models that assume durable population-level protection.

Safety and Adverse Events

Common Local and Systemic Reactions

Common local reactions to the DTaP vaccine, administered to infants and young children, primarily consist of pain, redness, and swelling at the injection site, affecting 20% to 50% of recipients depending on the dose and formulation. These reactions are typically mild, self-limiting, and resolve within 1 to 3 days without intervention. Frequencies tend to increase with subsequent doses, particularly boosters in preschool-aged children, where large local reactions (redness or swelling ≥50 mm) occur in 19% to 33% of cases. In contrast, the Tdap formulation used in adolescents and adults exhibits lower rates of injection-site reactions, often reported as pain or mild swelling in under 25% of doses. Systemic reactions are generally mild and include low-grade fever (≥100.4°F or 38°C), or fussiness, , and loss of , occurring in 1% to 20% of DTaP doses, with fever rates of 8% to 20% following primary series doses (1 through 3). These effects peak within 24 to 48 hours post-vaccination and resolve spontaneously within 1 to 3 days. Systemic events are more frequent after early doses in infants, while local reactogenicity rises with boosters, potentially linked to immune memory or adjuvant components like aluminum salts, though most remain transient and non-debilitating. Surveillance data from clinical trials and post-marketing studies confirm these patterns, with overall solicited reaction rates of 70% to 75% across local and systemic symptoms in controlled settings. or drowsiness may accompany these in up to 15% to 30% of young children but seldom requires medical attention.

Rare Serious Events and Risk Assessment

Rare serious adverse events following diphtheria-tetanus-pertussis (DTP) or diphtheria-tetanus-acellular pertussis (DTaP) include neurologic conditions such as and seizures, as well as . For the acellular DTaP formulations used since the 1990s, the incidence of remains extremely low, with reporting rates estimated at approximately 1.3 cases per 10 million doses among pediatric populations. These events are often non-specific or coincidental, lacking confirmed causality in large-scale surveillance like the Vaccine Safety Datalink (VSD). Febrile seizures, the predominant seizure type post-DTaP, occur at rates below 4 per 100,000 doses, typically in the context of fever triggered by , with no evidence of long-term neurologic sequelae. In contrast, historical whole-cell DTP vaccines were associated with higher risks; febrile seizures occurred in about 1 in 1,750 doses, and with residual damage was estimated at 1 per 310,000 doses, though causality for the latter was not definitively established due to confounding factors like underlying infections. Anaphylaxis, a severe allergic reaction, follows DTaP or Tdap administration at rates of 1.3 to 1.5 cases per million doses, based on (VAERS) and VSD data spanning millions of administrations. These events usually manifest within minutes to hours post-vaccination and are managed with epinephrine, with mortality exceedingly rare. Guillain-Barré (GBS), a , shows no confirmed causal association with DTaP vaccines; large cohort studies report zero cases in risk intervals following tens of thousands of doses, and VAERS signals lack temporal clustering beyond background rates. Risk-benefit assessments by agencies like the CDC and WHO conclude that the prevention of , , and pertussis—diseases with case-fatality rates up to 20% for pertussis in infants—far exceeds these rare event risks, averting millions of cases annually through . Nonetheless, absolute risks, though minimal (e.g., <1 per 100,000 for serious neurologic events with DTaP), are non-zero, particularly for individuals with predisposing factors like prior allergies or family seizure history, warranting individualized evaluation in low-prevalence settings. Surveillance systems like VAERS and VSD provide ongoing monitoring, but passive reporting may underestimate or overestimate due to underreporting of mild events and stimulated reporting post-publicity.

Comparisons Across Formulations

The whole-cell formulation of the exhibits a higher reactogenicity profile than acellular pertussis-containing versions, with clinical trials documenting systemic reactions such as fever exceeding 39°C in approximately 25–50% of recipients following whole-cell doses, alongside local reactions like extensive swelling and erythema. In contrast, acellular formulations typically elicit milder responses, with fever rates of 5–10% and reduced incidence of injection-site pain or redness. Hypotonic-hyporesponsive episodes (HHE), characterized by sudden limpness and unresponsiveness, occur in about 1% of whole-cell doses (roughly 1 per 100–1,750 vaccinations), often within 48 hours, whereas these are markedly rarer with acellular vaccines, reported at rates below 0.1%.
Adverse EventWhole-Cell RateAcellular Rate
High fever (>39–40.5°C)25–50% of doses5–10% of doses
Hypotonic-hyporesponsive episodes (HHE)~1% (1 per 100–1,750 doses)<0.1% (1 per 10,000+ doses)
Severe local reactions (e.g., extensive swelling)Up to 10–20% per dose1–5% per dose
This disparity in adverse event profiles prompted policy transitions in multiple countries during the 1990s, including the United States' endorsement of acellular vaccines for routine infant use starting in 1997, driven by public and medical concerns over whole-cell tolerability rather than confirmed causal links to permanent neurological harm. Post-switch surveillance indicated a substantial decline in reported reactions, with acellular programs correlating to fewer HHE and febrile events, though variations in reporting systems—such as pre-switch emphasis on whole-cell risks—may introduce ascertainment biases that inflate historical comparisons. The emphasis on reactogenicity reduction facilitated higher vaccination compliance but highlighted a safety trade-off, as acellular formulations, while minimizing acute events, necessitate more frequent boosters due to observed differences in immune response durability.

Administration and Recommendations

Pediatric and Booster Schedules

The recommended pediatric schedule for the DTaP (diphtheria, tetanus, and acellular pertussis) vaccine in the United States, as endorsed by the Centers for Disease Control and Prevention (CDC), consists of a primary series of three doses administered at 2, 4, and 6 months of age, followed by booster doses at 15–18 months and 4–6 years. This five-dose regimen aims to achieve and sustain protective antibody levels, with post-primary series seroprotection rates typically exceeding 95–100% for diphtheria and tetanus toxoids based on thresholds of ≥0.1 IU/mL for diphtheria and ≥0.01 IU/mL for tetanus. For pertussis antigens, immunogenicity is evaluated through anti-pertussis toxin antibody geometric mean concentrations, which rise substantially after the primary series but begin waning within 1–2 years, justifying the timed boosters to restore thresholds associated with efficacy. The World Health Organization (WHO) aligns closely with this approach for DTP (whole-cell or acellular pertussis formulations), recommending a primary series of three doses starting as early as 6 weeks of age, with intervals of 4–8 weeks between doses (typically completing by 14–18 weeks), and a first booster at 9–12 months or later in the second year of life. Subsequent preschool boosters are advised around 4–6 years to extend protection into school age, grounded in data showing that primary immunization alone induces short-term immunity insufficient against pertussis resurgence without reinforcement. Annual boosters are not routine in pediatric protocols, as schedules are calibrated to immunogenicity decay curves rather than continuous dosing, with evidence indicating that the 4–6 year booster maintains adequate humoral responses until adolescence without excessive antigen exposure. Incomplete adherence to this schedule creates vulnerability windows, particularly for pertussis, where delays in doses beyond recommended ages correlate with higher infection risk in undervaccinated children under 2 years. Studies report DTaP series completion rates improving over time but remaining suboptimal at around 80–90% by age 2 in some U.S. cohorts, with each missed or delayed dose extending periods of low antibody levels and contributing to outbreak susceptibility. Such gaps underscore the importance of timely administration to minimize epidemiological risks during critical infancy and toddler periods.

Use in Adults and Special Populations

The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged 19 years and older receive a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine if they have not previously received it, followed by tetanus-diphtheria (Td) or Tdap boosters every 10 years to maintain protection against tetanus and diphtheria, with the pertussis component primarily from the initial Tdap dose. This schedule prioritizes sustained immunity against tetanus and diphtheria, as pertussis protection wanes over time, but routine repeat Tdap dosing beyond the initial adult dose is not universally mandated due to limited evidence of added benefit against pertussis resurgence in adults. For pregnant individuals, ACIP advises administering Tdap during the third trimester (27–36 weeks gestation) of each pregnancy, ideally earlier in this window, to transfer pertussis-specific antibodies to the fetus via the placenta, thereby providing passive protection to infants in their first months of life before they can be fully vaccinated. Studies indicate this strategy reduces pertussis incidence in infants younger than 2 months by approximately 78%, with no evidence of increased fetal or maternal adverse outcomes beyond routine vaccine reactions. Maternal Tdap vaccination has been associated with interrupting rising pertussis trends in young infants, though effectiveness may vary by timing and population factors. In immunocompromised adults, including those with HIV or undergoing chemotherapy, Tdap is recommended per the standard adult schedule without dose adjustments, as it is an inactivated vaccine with no live components, posing minimal risk of exacerbation in such populations. For severely immunocompromised individuals lacking prior vaccination history, a primary series may be initiated with Tdap preferred for the first dose, though antibody responses could be suboptimal, necessitating clinical monitoring rather than additional doses solely for immunogenicity enhancement. Tdap formulations contain no egg-derived components, eliminating concerns relevant to other vaccines like influenza in egg-allergic patients.

International Variations

In Europe, hexavalent vaccines combining diphtheria, tetanus, pertussis (DTP) with inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), and hepatitis B are routinely used in infant schedules, typically administered at 2, 3-4, and 5-6 months of age, followed by boosters around 11-18 months and later in childhood. Countries such as the United Kingdom and France prioritize maternal Tdap vaccination, recommended from 16-20 weeks of gestation, to confer passive immunity to infants before their primary DTP series begins at 2 months. In developing countries, the World Health Organization endorses an accelerated DTP schedule of doses at 6, 10, and 14 weeks of age to enable early protection amid high disease burdens and logistical constraints. Vaccine supply disruptions, including those exacerbated by the , have led to coverage declines—such as a 5% global drop in DTP3 from 2019 to 2021—and associated outbreaks, notably diphtheria resurgences in West Africa linked to inadequate storage and distribution in low-resource settings. Australia and the Netherlands maintain high DTP coverage rates exceeding 90-93%, yet experience recurrent pertussis epidemics every 3-4 years, with peaks among adolescents and adults despite routine infant vaccination and boosters, underscoring ongoing transmission cycles in highly immunized populations.

Controversies and Policy Debates

Challenges with Pertussis Resurgence Despite Vaccination

Despite widespread use of diphtheria-tetanus-acellular pertussis (DTaP) vaccines, pertussis incidence has resurged in numerous countries, including the United States, since the late 1990s following the shift from whole-cell pertussis (wP) to acellular pertussis (aP) formulations. This resurgence manifests as cyclical epidemics, with U.S. cases peaking at over 48,000 reported in 2012, far exceeding pre-vaccine era declines but not matching historical highs. Empirical data indicate that aP-induced immunity wanes rapidly, often within 2–4 years post-vaccination, conferring shorter and less robust protection against infection compared to wP or natural immunity, which sustain longer-term mucosal and cellular responses. Animal models and human studies demonstrate that aP vaccines primarily mitigate severe disease symptoms but fail to prevent nasopharyngeal colonization or onward transmission, enabling vaccinated individuals to harbor Bordetella pertussis asymptomatically and propagate outbreaks. A key biological driver is the pathogen's antigenic evolution, where circulating B. pertussis strains have diverged from vaccine targets through mutations in genes encoding pertussis toxin (ptxA/ptxP3), pertactin (prn, e.g., prn2 allele predominance), and fimbriae (fim3-2 allele shift). These changes, documented via genomic sequencing, reduce vaccine efficacy by creating mismatches; for instance, ptxP3 strains produce higher toxin levels, evading antibody neutralization, while fim3 polymorphisms alter surface antigens critical for adherence and immunity. Such adaptations, accelerated post-vaccination era, parallel selective pressures observed in other pathogens, undermining herd immunity as vaccine-strain-specific responses falter against evolved variants. Behavioral and surveillance factors exacerbate the issue, with underreporting prevalent among adults due to atypical, milder presentations mimicking bronchitis, compounded by waning adult boosters and diagnostic challenges. Adults, often partially immune from prior vaccination or infection, serve as silent reservoirs, transmitting to unvaccinated or waning infants; estimates suggest true adult incidence may exceed reported figures by 10–100-fold based on serological surveys. Improved hygiene and living standards have reduced overall severity and mortality, masking the persistent circulation and true epidemiological burden in vaccinated populations. This underascertainment perpetuates epidemics, as enhanced diagnostics reveal higher baseline transmission than previously assumed.

Mandates, Exemptions, and Individual Risk-Benefit Analysis

In the United States, all 50 states and the District of Columbia mandate diphtheria, tetanus, and acellular pertussis (DTaP) vaccination as a condition for public school entry, typically requiring four to five doses by kindergarten with boosters in adolescence. Medical exemptions are permitted nationwide, based on contraindications documented by physicians, while religious exemptions are allowed in 45 states, and philosophical or personal belief exemptions in 15 states including Arizona, Idaho, and Oregon. Five states—California, Maine, Mississippi, New York, and West Virginia—prohibit non-medical exemptions entirely, following legislative changes such as California's Senate Bill 277 in 2015, which eliminated personal belief exemptions amid pertussis outbreaks. Similar requirements apply to childcare and some workplaces, particularly for healthcare personnel via Tdap boosters, enforced through state health departments. Exemption rates remain low nationally, at 3.3% for kindergarteners in the 2023–24 school year, with non-medical exemptions clustering geographically in certain counties and correlating with localized pertussis incidence increases. Geospatial analyses have identified overlaps between high-exemption kindergarten clusters and pertussis case clusters among children aged 3–18, with exempt children facing elevated odds of infection (approximately 5–6 times higher in meta-analyses). However, these exemptions account for a minority of overall cases, as pertussis incidence persists in states with stringent mandates and vaccination coverage exceeding 92%, driven primarily by waning immunity from acellular formulations rather than exemption prevalence. For instance, national pertussis cases reached several thousand annually in recent years despite high DTaP uptake, with 2025 reporting an uptick independent of exemption trends. Policy debates highlight tensions between mandates and individual autonomy, with critics arguing that uniform requirements overlook heterogeneous disease risks, such as lower baseline pertussis incidence (typically 1–2 cases per 100,000 in low-prevalence areas) where marginal personal benefits may not justify coercion for all. Legal challenges, including post-SB277 lawsuits in California, have upheld mandates under precedents like Jacobson v. Massachusetts (1905), which permits public health interventions absent fundamental rights violations, but proponents of broader exemptions contend for proportionality reviews given breakthrough infections in vaccinated cohorts. Empirical cost-benefit considerations favor informed consent models in settings with minimal herd immunity gaps, as rare exemptions do not predominantly drive epidemics, per analyses showing stronger associations with vaccine duration efficacy than exemption clusters. Such approaches prioritize causal factors like immunity decay over blanket policies, though mainstream public health sources, often institutionally aligned with mandate expansion, emphasize exemption reductions to minimize any attributable risk.

Historical Incidents and Public Trust Issues

In the United Kingdom during the mid-1970s, public alarm over the whole-cell pertussis component of the DPT vaccine escalated following media coverage and a 1974 television documentary claiming associations with encephalopathy and permanent brain damage in children. Vaccination rates plummeted from around 80% in 1972 to approximately 30% by 1978, correlating with a sharp increase in pertussis cases and fatalities, including over 100 deaths in young children between 1978 and 1979. Subsequent epidemiological investigations, including cohort studies, found no causal link between the vaccine and chronic neurological disorders, attributing many reported incidents to coincidence or misdiagnosis, though the episode entrenched skepticism toward vaccine safety claims by authorities. Sweden withdrew recommendations for pertussis vaccination in 1979 after the National Board of Health concluded that the risks of adverse reactions, including reported neurological events, outweighed benefits based on contemporary data. This suspension persisted until 1996, during which pertussis incidence quadrupled compared to pre-withdrawal levels, with outbreaks in 1983 and 1985 affecting thousands, including severe cases in infants. Resumption with acellular formulations later reduced cases, but the policy reversal highlighted how safety perceptions, amplified by limited early evidence, disrupted herd immunity and amplified disease burden. In the United States, a surge of litigation in the early 1980s accused DPT manufacturers of causing seizures and brain damage, culminating in over 250 lawsuits by 1986 that drove several firms from the market and risked vaccine shortages. The , enacted on November 14, 1986, responded by creating a no-fault compensation system funded by an excise tax on vaccines, compensating verified injuries while granting manufacturers immunity from civil suits to stabilize supply. From 1988 to 2023, the program awarded over $5 billion for claims including those linked to DPT, though petitioners must prove causation, and many historical allegations of widespread harm were not substantiated in court or post-hoc reviews. Ongoing scrutiny of the Vaccine Adverse Event Reporting System (VAERS), established in 1990, reveals passive reports of serious events following DPT administration, with underreporting estimated at factors of 10 to 100 for milder reactions but lower for fatalities. Analyses of VAERS data from the 1990s onward identified rare associations, such as hypotonic-hyporesponsive episodes, but no patterns of causality for long-term disabilities beyond acknowledged risks like acute encephalopathy in 0.0006% to 0.01% of doses. These systems have sustained public distrust, particularly amid perceptions of incomplete transparency, despite investigations consistently affirming the vaccine's net safety profile through controlled studies.

Epidemiological Impact

Pre-Vaccine Era Disease Burden

Prior to widespread vaccination in the mid-20th century, diphtheria, pertussis, and tetanus imposed substantial morbidity and mortality, particularly among children in the United States and Europe, where annual death tolls reached thousands despite improving public health measures. These bacterial infections thrived in environments of overcrowding, poor sanitation, and limited access to medical care, with transmission facilitated by close contact and contaminated wounds or fomites. Diagnosis relied on clinical presentation corroborated by laboratory methods, such as throat cultures for Corynebacterium diphtheriae toxin production in diphtheria, characteristic paroxysmal coughing in pertussis, and muscle spasms with wound history in tetanus, ensuring reasonable consistency in reported cases despite diagnostic limitations of the era. In the United States during the 1920s, diphtheria caused an estimated 13,000 to 15,000 deaths annually, accounting for a significant portion of pediatric fatalities, with case numbers peaking at over 200,000 in 1921. The disease manifested as a respiratory infection forming a thick pseudomembrane in the throat, leading to airway obstruction, myocarditis, and toxemia, with case-fatality rates of 5-10% even under optimal care. Europe experienced similar burdens, with urban epidemics exacerbated by population density, though exact figures varied by country due to underreporting. Pertussis, or whooping cough, struck with even greater frequency, reporting over 200,000 cases yearly in the United States before the 1940s, alongside approximately 9,000 deaths, predominantly in infants under one year whose small airways were prone to severe respiratory distress and secondary pneumonia. Globally, the disease affected millions, contributing to high infant mortality in densely populated regions with inadequate nutrition and hygiene. Clinical diagnosis centered on the inspiratory whoop following coughing fits, with historical confirmation via cough plate cultures isolating Bordetella pertussis, though many mild cases evaded detection. Tetanus, resulting from Clostridium tetani spores entering wounds, yielded fewer but consistently lethal cases, with around 500 deaths reported annually in the pre-vaccine United States, reflecting a case-fatality rate exceeding 50% due to respiratory failure from rigid spasms. Incidence correlated with trauma in agrarian or wartime settings, amplified by soil contamination and delayed wound care; neonatal tetanus added to global burdens in areas with unhygienic birth practices. Diagnosis was clinical, based on trismus (lockjaw) and generalized rigidity, without routine toxin assays until later decades, underscoring the disease's reliance on preventive antisepsis rather than treatment.
DiseaseU.S. Annual Cases (Pre-1940s Average)U.S. Annual Deaths (Pre-1940s Average)
Diphtheria~150,000-200,00010,000-15,000
Pertussis>200,000~9,000
TetanusNot routinely tracked (sporadic)~500

Post-Vaccination Reductions and Breakthrough Cases

Following the introduction of diphtheria-tetanus-pertussis (DTP) vaccines in the mid-20th century, reported cases of declined sharply from peaks of 100,000–200,000 annually in the 1920s to fewer than five cases per year since the . Between 1996 and 2018, only 14 cases were documented, with one death, reflecting near-elimination attributable to high vaccine coverage and efficacy exceeding 95%. Tetanus incidence similarly plummeted, with sporadic cases averaging around 30 annually in recent decades, down from hundreds pre-vaccination; nearly all occur in unvaccinated or inadequately vaccinated individuals, underscoring the toxoid's near-100% protective against clinical . In contrast, pertussis cases dropped approximately 90% from an estimated 200,000 annually before widespread to 10,000–20,000 in typical pre-pandemic years, yet the persists endemically with outbreaks driven by breakthrough infections. Despite rates often exceeding 90% among children, a substantial proportion of cases—approaching 50% or more in some school outbreaks—involve fully vaccinated individuals, reflecting waning immunity from acellular pertussis components and incomplete prevention of transmission. Improvements in and contributed to initial 20th-century declines in these diseases by reducing exposure, but sustained low incidence levels correlate directly with , as evidenced by case clusters in under-vaccinated populations and the absence of resurgence in highly immunized groups post-vaccine introduction. For and , vaccines provide durable sterilizing protection absent in sanitation alone, maintaining incidence near zero even as environmental risks persist. Pertussis persistence highlights vaccine limitations in achieving , with acellular formulations less effective at blocking compared to earlier whole-cell versions.

Global Disparities and Ongoing Challenges

Global coverage of the third dose of DPT vaccine (DTP3) reached 85% among infants in , yet disparities persist, with only 82% coverage in lower-income countries. These gaps are exacerbated in low socio-demographic index (SDI) regions, where weaker health systems and socioeconomic factors contribute to lower rates and higher incidence. In the 1990s, epidemics in highlighted vulnerabilities from disrupted vaccination programs, resulting in over 157,000 cases and 5,000 deaths across the former from 1990 to 1998. Neonatal tetanus remains a challenge in certain low-income settings despite global progress, with approximately 25,000 newborn deaths reported in 2018, reflecting persistent issues in maternal and hygienic delivery practices. While 47 priority countries achieved maternal and neonatal elimination between 2000 and 2022, leading to an 89% decline in neonatal cases, pockets of high incidence endure in regions like and due to inadequate coverage. Pertussis resurgence poses ongoing global challenges, driven by waning immunity from acellular vaccines, which protect for only 4–12 years post-vaccination, compared to longer durations from natural infection or whole-cell vaccines. This has led to cyclical outbreaks even in high-coverage areas, compounded by pathogen adaptations like genetic mutations in Bordetella pertussis. Migration and travel facilitate case importation, sustaining transmission in vaccinated populations with incomplete herd immunity. Research and development efforts focus on next-generation acellular vaccines with innovative adjuvants and antigens to extend protection duration and address these limitations. Without advancements in vaccine technology, pertussis epidemics are projected to continue, imposing substantial economic burdens; , annual pertussis cases of 20,000–40,000 contribute to significant healthcare and outbreak response costs.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4975064/
  2. https://www.ncbi.nlm.nih.gov/books/NBK545173/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC5919600/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC5710106/
  5. https://academic.oup.com/jpids/article/8/4/334/5359449
  6. https://www.ncbi.nlm.nih.gov/books/NBK234360/
  7. https://annalsofglobalhealth.org/articles/10.5334/aogh.2449
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5088088/
  9. https://www.pnas.org/doi/10.1073/pnas.1314688110
  10. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01344/full
  11. https://www.ncbi.nlm.nih.gov/books/NBK559015/
  12. https://www.cdc.gov/diphtheria/hcp/clinical-signs/index.html
  13. https://www.cdc.gov/diphtheria/symptoms/index.html
  14. https://emedicine.medscape.com/article/782051-clinical
  15. https://www.cdc.gov/diphtheria/about/index.html
  16. https://www.who.int/health-topics/diphtheria
  17. https://www.ncbi.nlm.nih.gov/books/NBK560911/
  18. https://historyofvaccines.org/history/diphtheria/overview/
  19. https://www.ncbi.nlm.nih.gov/books/NBK482484/
  20. https://www.ecdc.europa.eu/en/tetanus/facts
  21. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-21-tetanus.html
  22. https://www.merckmanuals.com/professional/infectious-diseases/anaerobic-bacteria/tetanus
  23. https://www.who.int/news-room/fact-sheets/detail/tetanus
  24. https://www.cdc.gov/tetanus/about/index.html
  25. https://emedicine.medscape.com/article/229594-overview
  26. https://www.sciencedirect.com/science/article/pii/S1201971225000050
  27. https://www.cdc.gov/global-tetanus-vaccination/impact/index.html
  28. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/tetanus
  29. https://www.sciencedirect.com/topics/immunology-and-microbiology/clostridium-tetani
  30. https://www.cdc.gov/pertussis/about/index.html
  31. https://www.ncbi.nlm.nih.gov/books/NBK519008/
  32. https://www.ncbi.nlm.nih.gov/books/NBK7813/
  33. https://www.cdc.gov/infection-control/hcp/healthcare-personnel-epidemiology-control/pertussis.html
  34. https://www.cdc.gov/pertussis/hcp/clinical-overview/index.html
  35. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-16-pertussis.html
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8604168/
  37. https://www.who.int/health-topics/pertussis
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8482022/
  39. https://www.cdc.gov/pertussis/php/surveillance/index.html
  40. https://www.bmj.com/content/389/bmj.r704
  41. https://www.cdc.gov/Mmwr/preview/mmwrhtml/00038200.htm
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC11752783/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3298325/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC1861415/
  45. https://www.lifesciencehistory.com/diphtheria-and-tetanus-toxoids-and-pertussis-dtp-was-licensed/
  46. https://www.ncbi.nlm.nih.gov/books/NBK234373/
  47. https://www.nature.com/articles/d42859-020-00013-8
  48. https://pubmed.ncbi.nlm.nih.gov/15889991/
  49. https://onlinelibrary.wiley.com/doi/10.1111/j.1442-200x.2004.01970.x
  50. https://www.nejm.org/doi/full/10.1056/NEJM199602083340602
  51. https://pubmed.ncbi.nlm.nih.gov/2896826/
  52. https://publications.aap.org/pediatrics/article/101/1/1/52322/A-Comparative-Efficacy-Trial-in-Germany-in-Infants
  53. https://www.cdc.gov/mmwr/preview/mmwrhtml/00015794.htm
  54. https://publications.aap.org/pediatrics/article/99/2/282/64708/Acellular-Pertussis-Vaccine-Recommendations-for
  55. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/pertussis
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3968808/
  57. https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/hcp/about-vaccine.html
  58. https://www.healthline.com/health/adult-vaccines/tdap-vs-dtap-vaccines-difference
  59. https://www.chop.edu/vaccine-education-center/vaccine-safety/vaccine-ingredients/ingredients-by-vaccine/dtap-vaccines-ingredients
  60. https://www.fda.gov/files/vaccines%252C%2520blood%2520%2526%2520biologics/published/Package-Insert-Adacel.pdf
  61. https://www.omegapediatrics.com/tdap-vaccine-dive-to-components-and-safety/
  62. https://www.cdc.gov/vaccines-children/about/combination-vaccines.html
  63. https://pro.campus.sanofi/us/products/pentacel
  64. https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-vaxelis.pdf
  65. https://www.gov.uk/government/publications/hexavalent-combination-vaccine-programme-guidance/hexavalent-dtapipvhibhepb-combination-vaccine-information-for-healthcare-practitioners
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC3068581/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7312233/
  68. https://academic.oup.com/jid/article/181/Supplement_1/S184/840264
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC6963617/
  70. https://academic.oup.com/cid/article/62/9/1111/1745278
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9203330/
  72. https://www.sciencedirect.com/science/article/pii/S1877282X10000299
  73. https://www.atrainceu.com/content/4-herd-immunity
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC9485965/
  75. https://www.nejm.org/doi/full/10.1056/NEJMoa1200850
  76. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197970
  77. https://publications.aap.org/pediatrics/article/133/3/e619/32892/Effectiveness-of-DTaP-Vaccine-in-Infants
  78. https://www.sciencedirect.com/science/article/pii/0264410X9090246I
  79. https://www.sciencedirect.com/science/article/pii/0264410X92900022
  80. https://www.nature.com/articles/s41467-024-44943-7
  81. https://academic.oup.com/cid/article/62/7/829/2463039
  82. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827556
  83. https://www.cdc.gov/pertussis/php/surveillance/pertussis-cases-by-year.html
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC5755965/
  85. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6128a1.htm
  86. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2731128
  87. https://publications.aap.org/pediatrics/article/129/5/968/73840/Why-Do-Pertussis-Vaccines-Fail
  88. https://www.pnas.org/doi/10.1073/pnas.1014394108
  89. https://academic.oup.com/jid/article/205/8/1220/877724
  90. https://www.mja.com.au/journal/2014/200/6/acellular-pertussis-vaccine-effectiveness-children-during-2009-2010-pertussis
  91. https://pubmed.ncbi.nlm.nih.gov/24702091/
  92. https://www.sciencedirect.com/science/article/pii/S1755436519300179
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC6882445/
  94. https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-021-00458-3
  95. https://wwwnc.cdc.gov/eid/article/28/5/21-1958_article
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC5710108/
  97. https://www.cdc.gov/vaccine-safety/vaccines/dtap-tdap.html
  98. https://publications.aap.org/pediatrics/article/127/3/e581/65025/Injection-Site-and-Risk-of-Medically-Attended
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC2690538/
  100. https://www.aafp.org/pubs/afp/issues/2017/0615/p786.html
  101. https://www.cdc.gov/vaccines/basics/possible-side-effects.html
  102. https://www.chop.edu/vaccine-education-center/vaccine-safety/other-vaccine-safety-concerns/fever-and-vaccines
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC6476554/
  104. https://www.fda.gov/media/74046/download
  105. https://www.pediarix.com/efficacy/clinical-data/
  106. https://www.sciencedirect.com/science/article/pii/S0264410X20305193
  107. https://www.vaccinesafety.edu/do-vaccines-cause-meningitis-or-encephalitis/
  108. https://www.uptodate.com/contents/diphtheria-tetanus-and-pertussis-immunization-in-children-6-weeks-through-6-years-of-age/print
  109. https://www.chop.edu/vaccine-education-center/vaccine-details/diphtheria-tetanus-and-pertussis-vaccines
  110. https://www.ncbi.nlm.nih.gov/books/NBK216824/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC6580415/
  112. https://publications.aap.org/pediatrics/article/112/4/815/63454/Risk-of-Anaphylaxis-After-Vaccination-of-Children
  113. https://www.jacionline.org/article/S0091-6749%2815%2901160-4/fulltext
  114. https://www.vaccinesafety.edu/do-vaccines-cause-guillain-barre-syndrome/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC10538447/
  116. https://www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm
  117. https://publications.aap.org/pediatrics/article/126/2/263/68662/Lack-of-Association-Between-Acellular-Pertussis
  118. https://karger.com/mpp/article/31/4/313/825084/Whole-Cell-and-Acellular-Pertussis-Vaccine
  119. https://jamanetwork.com/journals/jamapediatrics/fullarticle/514936
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC5489273/
  121. https://bmjopen.bmj.com/content/7/1/e012945
  122. https://www.cmaj.ca/content/175/10/1213
  123. https://www.cdc.gov/mmwr/preview/mmwrhtml/00048610.htm
  124. https://pubmed.ncbi.nlm.nih.gov/30143272/
  125. https://academic.oup.com/aje/article/176/11/1035/178176
  126. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
  127. https://www.immunize.org/clinical/a-z/dtap-tdap-td-catch-up-vaccination-recommendations-history-age/
  128. https://www.sciencedirect.com/science/article/pii/S0264410X19315063
  129. https://pmc.ncbi.nlm.nih.gov/articles/PMC8299947/
  130. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/pertussis
  131. https://www.gavi.org/our-support/guidelines/dtp-containing-vaccine-boosters-programme-information
  132. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/0911_GUI_Scientific_Panel_on_Childhood_Immunisation_DTP.pdf
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC6351022/
  134. https://publications.aap.org/pediatrics/article/152/2/e2022059844/192854/Failure-to-Complete-Multidose-Vaccine-Series-in
  135. https://www.sciencedirect.com/science/article/pii/S0264410X19302269
  136. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
  137. https://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm
  138. https://www.cdc.gov/pertussis/vaccines/tdap-vaccination-during-pregnancy.html
  139. https://pmc.ncbi.nlm.nih.gov/articles/PMC5754921/
  140. https://www.cdc.gov/pertussis/hcp/vaccine-recommendations/pregnancy-research.html
  141. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html
  142. https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules/adult-immunization-schedule.html
  143. https://www.uptodate.com/contents/tetanus-diphtheria-toxoid-vaccination-in-adults/print
  144. https://www.cdc.gov/acip-recs/hcp/vaccine-specific/dtap-tdap-td.html
  145. https://www.gavi.org/our-support/guidelines/hexavalent-vaccine-programme-information
  146. https://www.epicentro.iss.it/en/vaccines/immunization-schedule-italy
  147. https://www.nhs.uk/pregnancy/keeping-well/whooping-cough-vaccination/
  148. https://www.sciencedirect.com/science/article/pii/S0264410X24011848
  149. https://pmc.ncbi.nlm.nih.gov/articles/PMC10305165/
  150. https://pmc.ncbi.nlm.nih.gov/articles/PMC10683557/
  151. https://stacks.cdc.gov/view/cdc/14988/cdc_14988_DS1.pdf
  152. https://www.mcri.edu.au/news/insights-and-opinions/whooping-cough-deadly-young-babies-vaccination-best-defence
  153. https://www.journalpulmonology.org/en-unraveling-resurgence-pertussis-insights-into-articulo-S2531043724000552
  154. https://pubmed.ncbi.nlm.nih.gov/26103968/
  155. https://pmc.ncbi.nlm.nih.gov/articles/PMC9151166/
  156. https://www.cambridge.org/core/journals/epidemiology-and-infection/article/pertussis-resurgence-waning-immunity-and-pathogen-adaptation-two-sides-of-the-same-coin/2C4624385819C751F0C4E9448D4ABF04
  157. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046407
  158. https://www.tandfonline.com/doi/full/10.1586/erv.12.83
  159. https://link.springer.com/article/10.1007/s40121-023-00895-x
  160. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-015-1269-1
  161. https://www.sciencedirect.com/science/article/pii/S0264410X24006753
  162. https://pmc.ncbi.nlm.nih.gov/articles/PMC12153400/
  163. https://www.cdc.gov/phlp/docs/school-vaccinations.pdf
  164. https://www.ncsl.org/health/state-non-medical-exemptions-from-school-immunization-requirements
  165. https://www.reuters.com/business/healthcare-pharmaceuticals/vaccine-requirements-exemptions-across-us-2025-09-05/
  166. https://www.immunize.org/official-guidance/state-policies/requirements/
  167. https://www.cdc.gov/mmwr/volumes/73/wr/mm7341a3.htm
  168. https://www.pnas.org/doi/10.1073/pnas.1700240114
  169. https://cidrap.umn.edu/childhood-vaccines/study-relates-vaccine-refusal-rise-measles-pertussis
  170. https://www.healio.com/news/infectious-disease/20170623/increase-in-pertussis-linked-to-nonmedical-vaccine-exemptions-waning-immunity
  171. https://www.sciencedirect.com/science/article/pii/S1755436523000257
  172. https://www.vaccineadvisor.com/news/united-states-seeing-uptick-in-pertussis-cases/
  173. https://pmc.ncbi.nlm.nih.gov/articles/PMC5007135/
  174. https://www.nejm.org/doi/full/10.1056/NEJMsa0806477
  175. https://dash.harvard.edu/bitstream/handle/1/33797295/ALOE-DOCUMENT-2016.pdf?isAllowed=y&sequence=1
  176. https://www.cdc.gov/vaccines/php/requirements-laws/state-vaccination-requirements.html
  177. https://pubmed.ncbi.nlm.nih.gov/12922137/
  178. https://pubmed.ncbi.nlm.nih.gov/8483621/
  179. https://academic.oup.com/jid/article/224/Supplement_4/S310/6378082
  180. https://news.ki.se/new-whooping-cough-vaccine-shows-promise
  181. https://scholarship.law.wm.edu/cgi/viewcontent.cgi?article=1514&context=wmlr
  182. https://www.hrsa.gov/vaccine-compensation/about
  183. https://pmc.ncbi.nlm.nih.gov/articles/PMC11252891/
  184. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-7-diphtheria.html
  185. https://historyofvaccines.org/history/diphtheria/timeline/
  186. https://jamanetwork.com/journals/jama/fullarticle/254075
  187. https://news.ohsu.edu/2020/02/25/adults-dont-need-tetanus-diphtheria-boosters-if-fully-vaccinated-as-children-study-finds
  188. https://pmc.ncbi.nlm.nih.gov/articles/PMC6366372/
  189. https://www.vaccinesafety.edu/vaccine-preventable-diseases/
  190. https://www.cdc.gov/tetanus/php/surveillance/index.html
  191. https://health.hawaii.gov/docd/disease_listing/tetanus/
  192. https://www.mayoclinic.org/diseases-conditions/history-disease-outbreaks-vaccine-timeline/whooping-cough
  193. https://pmc.ncbi.nlm.nih.gov/articles/PMC4734526/
  194. https://www.gavi.org/news/media-room/2024-wuenic-immunisation-lower-income-countries
  195. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1597076/full
  196. https://academic.oup.com/jid/article/181/Supplement_1/S10/837378
  197. https://www.cdc.gov/mmwr/volumes/73/wr/mm7328a1.htm
  198. https://www.sciencedirect.com/science/article/pii/S0163445324002238
  199. https://pmc.ncbi.nlm.nih.gov/articles/PMC12351750/
  200. https://pmc.ncbi.nlm.nih.gov/articles/PMC11037283/
Add your contribution
Related Hubs
User Avatar
No comments yet.